A systematic review of smartphone apps for gastro-oesophageal reflux disease: the need for regulation and medical professional involvement.
Gastro-oesophageal Reflux Disease (GORD)
Smartphone applications
mobile health (mHealth)
Journal
mHealth
ISSN: 2306-9740
Titre abrégé: Mhealth
Pays: China
ID NLM: 101678564
Informations de publication
Date de publication:
2021
2021
Historique:
received:
10
06
2020
accepted:
31
01
2021
entrez:
22
11
2021
pubmed:
23
11
2021
medline:
23
11
2021
Statut:
epublish
Résumé
Expansion in smartphone use and mobile health (mHealth) apps has generated a large and unregulated sector. Gastro-oesophageal Reflux Disease (GORD) is a widely prevalent disease in the UK. The aim of this study is to evaluate the smartphone apps focused on GORD, available on major digital platforms, with particular emphasis on their recorded evidence base (EB) and the extent of medical professional involvement (MPI) in their constitution. Relevant apps were extracted using defined search terms and inclusion (using a wide array of search terms) and exclusion criteria (non-English language, duplicates) were applied. Data was collected from the overview provided by the developer in the app store and from the developer website for each app, and classified according to various variables. EB and professional involvement data was obtained from the application details provided in the app stores as well as information section of individual apps. A vast majority of the apps (97.3%) were developed targeting the general public. Of the 73 apps, 11 (15.1%) had a documented EB. Two apps stated if healthcare professionals were involved in the development, screening or assessment of the app content, meaning only 2.73% of the apps (2/73) stated their content had been contributed by medical professionals (individual, group or organisation of health providers). Thirty-four apps had recent updates in 2019 (47%, 34/73). Regulation and accreditation of mHealth apps related to GORD are needed.
Sections du résumé
BACKGROUND
BACKGROUND
Expansion in smartphone use and mobile health (mHealth) apps has generated a large and unregulated sector. Gastro-oesophageal Reflux Disease (GORD) is a widely prevalent disease in the UK. The aim of this study is to evaluate the smartphone apps focused on GORD, available on major digital platforms, with particular emphasis on their recorded evidence base (EB) and the extent of medical professional involvement (MPI) in their constitution.
METHODS
METHODS
Relevant apps were extracted using defined search terms and inclusion (using a wide array of search terms) and exclusion criteria (non-English language, duplicates) were applied. Data was collected from the overview provided by the developer in the app store and from the developer website for each app, and classified according to various variables. EB and professional involvement data was obtained from the application details provided in the app stores as well as information section of individual apps.
RESULTS
RESULTS
A vast majority of the apps (97.3%) were developed targeting the general public. Of the 73 apps, 11 (15.1%) had a documented EB. Two apps stated if healthcare professionals were involved in the development, screening or assessment of the app content, meaning only 2.73% of the apps (2/73) stated their content had been contributed by medical professionals (individual, group or organisation of health providers). Thirty-four apps had recent updates in 2019 (47%, 34/73).
CONCLUSIONS
CONCLUSIONS
Regulation and accreditation of mHealth apps related to GORD are needed.
Identifiants
pubmed: 34805387
doi: 10.21037/mhealth-20-126
pii: mh-07-20-126
pmc: PMC8572754
doi:
Types de publication
Journal Article
Langues
eng
Pagination
56Informations de copyright
2021 mHealth. All rights reserved.
Déclaration de conflit d'intérêts
Conflicts of Interest: All authors have completed the ICMJE uniform disclosure form (available at http://dx.doi.org/10.21037/mhealth-20-126). The authors have no conflicts of interest to declare.
Références
Ann Vasc Surg. 2013 Aug;27(6):804-9
pubmed: 23535521
JAMA Intern Med. 2018 Jun 1;178(6):802-809
pubmed: 29710289
BJU Int. 2011 Nov;108(9):1371-3
pubmed: 22023058
Stud Health Technol Inform. 2016;225:1030-1
pubmed: 27332467
Obes Surg. 2014 Jan;24(1):32-6
pubmed: 23749609
J Allergy Clin Immunol Pract. 2016 Jul-Aug;4(4):730-737.e1
pubmed: 27107690
Colorectal Dis. 2012 Sep;14(9):e530-4
pubmed: 22646729
Evid Based Med. 2013 Jun;18(3):90-2
pubmed: 22923708
J Psychiatr Res. 2018 Jan;96:239-246
pubmed: 29126059
Hernia. 2014 Aug;18(4):557-61
pubmed: 23801277
Curr Cardiol Rep. 2016 Dec;18(12):130
pubmed: 27826901
Breast. 2014 Oct;23(5):683-9
pubmed: 25153432
Healthc Inform Res. 2014 Jan;20(1):23-9
pubmed: 24627815
JMIR Mhealth Uhealth. 2019 Nov 26;7(11):e14730
pubmed: 31769758
JMIR Mhealth Uhealth. 2018 Jan 03;6(1):e2
pubmed: 29298749
Obes Surg. 2016 Jan;26(1):163-8
pubmed: 26424704